Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01214668 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT01214668 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 31 participants.
The verdict
NCT01214668, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The goal of this study is to determine the dose of LY573636-sodium (hereafter referred to as LY573636) that can be administered safely in combination with liposomal doxorubicin in patients with advanced cancer who have failed a prior treatment. The study consists of a dose escalation phase to the maximum tolerated dose (MTD) and a dose confirmation phase in patients with platinum resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have never been treated with doxorubicin.
Interventions
- DRUG Liposomal Doxorubicin
- DRUG LY573636-sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01214668
The ClinicalTrials.gov registry entry for NCT01214668 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal Doxorubicin is the first listed.
NCT01214668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01214668 about?
NCT01214668 is a clinical study titled "Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors". The goal of this study is to determine the dose of LY573636-sodium (hereafter referred to as LY573636) that can be administered safely in combination with liposomal doxorubicin in patients with advanced cancer who have failed a prior treatment. The study consists of a dose escalation phase to the m...
What is the current status of trial NCT01214668?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2009-01. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01214668?
The interventions under investigation include: Liposomal Doxorubicin (DRUG), LY573636-sodium (DRUG).
Who is sponsoring clinical trial NCT01214668?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.